RTW Venture Fund Limited specializes in identifying transformative assets with high growth potential across the life sciences, biopharmaceutical and medical technology sectors. The fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited

RTW is a life sciences investment and innovation firm. Headquartered in New York with offices in London and Shanghai, we invest across the full lifecycle of companies including company creation, early stage venture capital, alternative financing, and public company investments.

Biomea Fusion

Milestone Pharmaceuticals

NeoGenomics

Orchard Therapeutics

Prometheus Biosciences

2seventy bio

Allakos

Athira Pharma

Avidity Biosciences

Solid Biosciences

Stoke Therapeutics

Third Harmonic Bio

UroGen Pharma

C4 Therapeutics

CinCor Pharma

GH Research

immatics biotechnologies

Immunic Therapeutics

Rocket Pharmaceuticals

Roivant Sciences

Ventyx Biosciences

Science 37

Pulmonx

REGENXBIO

Renovacor

Immunocore

RTW Investments, LP

On National Intern Day we want to recognize our 2023 summer intern class.

Our exceptional group of interns has been actively engaged in various summer projects, ranging from research and development tracking to fundraising coordination, data organization, and therapeutic asset research. We extend our gratitude to Stela Sota, Halle Fiedler, Yifei Zhang, Sophie Takmopoulos, Karan Naik, Vincent Masto, and Yen-Der Li, MD, PhD for their dedicated efforts and hard work!

#Interns #RTWInterns #NationalInternday #InternAppreciation

This morning we announced Igor Splawski has joined RTW’s Yarrow Biotechnology as Chief Scientific Officer. Thanks to Lei Lei Wu for the Endpoints News Peer Review piece highlighting Igor’s unique style and deep expertise. Welcome to the team, Igor!

https://lnkd.in/gZPCXztt

Our managing director and CIO, Roderick Wong recently sat down with Daniel Coatsworth for AJ Bell’s Money and Markets podcast. The two discussed biotech M&A trends, our approach to investing in therapies targeting rare diseases, and some of the companies Rod’s excited about right now. The full episode featuring insights on the mortgage market and higher interest rate impacts on other sectors can be found at the below link. Rod’s portion starts just before the 27-minute mark. 

#biotech #investing #lifesciences 

https://lnkd.in/efJMxFJN

Investing in life sciences means not only believing in the power of science but understanding it. Our team of scientists, investors, and entrepreneurs digs deep to identify the most promising innovations and foster them to ensure they have the best chance of creating real life-changing impact on patients. Hear more about how science shapes our approach to investing. Featuring voiceover by our very own Hanah Gershkowitz.

Our purpose goes beyond short-term financial gains. It’s about powering the next innovations that will transform lives. Hear more about why we do what we do through the voice of our own Paula Boone.

Our culture at RTW is shaped by our people, our values, and the passion we share for powering innovative science to impact millions of lives. Hear more about what it’s like to work at RTW as told by our people.

#lifesciences #culture #investing #biotech

#ICYMI: Roderick Wong recently sat down with Capital Allocators’ Ted Seides to share his views on life sciences investing, the growth and evolution of RTW over the years, and some of the lessons he’s learned along the way. 
https://lnkd.in/eJjekwvm

#lifesciences #biotech #investing

Congrats to the ACELYRIN, INC. team on its Nasdaq debut. We're proud to continue to support the company in its mission to develop treatments for patients with inflammatory conditions.

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	27.92M -	38.72M 38.66%	160.65M 314.93%	-64.34M 140.05%	-39.44M 38.71%	83.19M 310.95%
depreciation and amortization
deferred income tax
stock based compensation
change in working capital	26.34K -	1.18M 4,362.62%	-1.32M 212.42%	38.75M 3,033.26%	-7.52M 119.39%	-26.39M 251.19%
accounts receivables		532.70K -	-1.07M 301.29%	830.88K 177.49%	4.83M 481.37%
inventory
accounts payables
other working capital		642.53K -	-248.93K 138.74%	37.92M 15,334.59%	-12.35M 132.55%
other non cash items	-27.99M -	-106.05M 278.86%	-216.48M 104.12%	-19.28M 91.09%	57.31M 397.21%	-23.26M 140.59%
net cash provided by operating activities	-44.28K -	-66.16M 149,306.92%	-57.14M 13.63%	-44.87M 21.47%	10.35M 123.07%	33.54M 223.95%
investments in property plant and equipment
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites
debt repayment			-33.42M -	-34.12M 2.08%
common stock issued		126.32M -	41.72M 66.97%	44.07M 5.63%
common stock repurchased		-16.37M -	-4.15M 74.66%	-4.97M 19.94%		-2.09M -
dividends paid			-4.15M -	-4.97M 19.94%
other financing activites		109.95M -	37.57M 65.83%	39.09M 4.05%
net cash used provided by financing activities		109.95M -	37.57M 65.83%	39.09M 4.05%		-2.09M -
effect of forex changes on cash
net change in cash	-44.28K -	43.78M 98,972.58%	-19.57M 144.70%	-5.78M 70.48%	10.35M 279.18%	31.45M 203.73%
cash at beginning of period	75.61K -	31.32K 58.57%	43.80M 139,721.17%	24.59M 43.86%	18.81M 23.50%	29.16M 55.05%
cash at end of period	31.32K -	43.82M 139,776.99%	24.23M 44.71%	18.81M 22.36%	29.16M 55.05%	60.61M 107.84%
operating cash flow	-44.28K -	-66.16M 149,306.92%	-57.14M 13.63%	-44.87M 21.47%	10.35M 123.07%	33.54M 223.95%
capital expenditure
free cash flow	-44.28K -	-66.16M 149,306.92%	-57.14M 13.63%	-44.87M 21.47%	10.35M 123.07%	33.54M 223.95%

COM:RTWFUNDS

RTW Funds

Last Close

1.19

25/04 15:35

Market Cap

502.74M

Beta: -

Volume Today

247.81K

Avg: -

Preview